Genta initiates prostate cancer drug trial
The study will assess tesetaxel as both first- and second-line chemotherapy. The study will evaluate two discrete populations: men with hormone/castrate-resistant prostate cancer, who have not previously received
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.